Aegis
AI platform automating insurance denial appeals for healthcare providers
Website: https://aegishealth.us/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | Aegis |
| Tagline | AI platform automating insurance denial appeals for healthcare providers |
| Headquarters | San Francisco, CA, USA |
| Founded | 2025 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed (total disclosed ~$500,000) |
Links
PUBLIC
Confirmed public links for Aegis are limited to its primary corporate presence.
- Website: https://www.ycombinator.com/companies/aegis
- LinkedIn: https://www.linkedin.com/company/aegis-yc-x25/
Data Accuracy: GREEN -- Confirmed by Y Combinator company directory and LinkedIn.
Executive Summary
PUBLIC Aegis is an early-stage AI platform that automates the insurance denial appeals process for healthcare providers, a wedge into a revenue recovery market estimated at over $260 billion annually [PMC] [Medical Economics]. The company, part of Y Combinator's Spring 2025 batch, aims to replace a manual, error-prone workflow with an integrated system for detection, generation, submission, and tracking of appeals [Y Combinator, Spring 2025].
Founded by three Carnegie Mellon University alumni, the team combines technical and analytical backgrounds: Aarav Bajaj brings machine learning experience from Palantir and CMU AI research, Krishang Todi contributes a background in economics and fixed-income risk modeling, and Dhanya Shah adds full-stack engineering expertise [Y Combinator, Spring 2025]. Their initial $500,000 seed funding from Y Combinator supports a four-person team that has reportedly generated $440,000 in revenue [GetLatka].
The business model is SaaS, targeting hospital billing departments and medical billing firms. The immediate focus is on proving product-market fit and moving beyond early revenue to secure initial enterprise customers in a sector known for long sales cycles and complex integration requirements. Over the next 12-18 months, the key signals to watch will be the announcement of named provider customers, the scaling of the reported revenue figure, and the closing of an institutional seed or Series A round to fund expansion.
Data Accuracy: YELLOW -- Core company facts confirmed by Y Combinator launch materials; revenue figure from a single, unverified source; market size cited across multiple industry publications.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed (total disclosed ~$500,000) |
Company Overview
PUBLIC
Aegis emerged from Y Combinator's Spring 2025 batch as a newly formed entity targeting healthcare's administrative bottlenecks. The company was founded by three Carnegie Mellon University alumni, Aarav Bajaj, Dhanya Shah, and Krishang Todi, who leveraged their close friendship and complementary technical backgrounds to address the manual, error-prone process of insurance denial appeals [Y Combinator, Spring 2025]. The founding team incorporated the company as Aegis Health Technology Corporation and established its headquarters in San Francisco, California [Crunchbase].
The company's primary public milestone is its acceptance into and launch from the Y Combinator accelerator program in early 2025. This event constituted its formal market entry and provided an initial $500,000 in seed capital under the program's standard terms [Y Combinator, Spring 2025]. No earlier corporate history, prior pivots, or subsequent funding rounds have been disclosed in public records.
Data Accuracy: YELLOW -- Company details confirmed via Y Combinator launch page and Crunchbase profile; founding narrative sourced from YC materials.
Product and Technology
MIXED Aegis positions its core product as an automated revenue recovery engine, a system designed to identify and contest insurance claim denials on behalf of healthcare providers. The platform’s stated workflow begins with denial detection, pulling data from integrated electronic health record (EHR) systems, clearinghouses, and payer portals [Y Combinator, Spring 2025]. From there, the system generates compliant appeal letters, handles submission, and provides tracking and analytics to monitor recovery rates and identify patterns in denials [Y Combinator, Spring 2025]. The company’s public framing emphasizes this end-to-end automation as a wedge to reduce manual, error-prone work for hospital billing teams.
The underlying technology stack is not detailed in public materials, but the product claims are centered on AI agents for document generation and workflow orchestration. The primary technical challenge implied is reliable integration with disparate healthcare data systems and the generation of appeals that adhere to complex, payer-specific clinical and administrative rules. No public demos, detailed feature lists, or API documentation are available to substantiate the depth of these integrations or the sophistication of the AI models used.
PUBLIC
The market for healthcare revenue recovery software is defined by a persistent, high-stakes operational bottleneck where legacy manual processes are being pressured by rising administrative costs and evolving reimbursement rules.
The total addressable market is anchored on the scale of denied claims. Multiple industry analyses cite a figure of approximately $260 billion in inpatient claims denied to hospital systems annually [PMC], [Medical Economics]. A separate Forbes Technology Council article frames the broader administrative bottleneck in healthcare billing at $300 billion [Forbes, Aug 2025]. Aegis cites the $260 billion figure as its target problem [YouTube]. While these figures represent the total value of denied claims, the serviceable addressable market for automation software is a fraction of this, based on the percentage of denials that are appealable and the fees providers are willing to pay to recover them. For context, the broader U.S. healthcare IT market was valued at $394.6 billion in 2024 and is projected to grow at a compound annual rate of 19.8% from 2024 to 2030, according to a Grand View Research report published in January 2025 (analogous market, source).
Demand is driven by several converging pressures on provider margins. Staff shortages in medical billing and coding roles increase the cost and delay of manual appeals. Payer policies and prior authorization requirements continue to grow in complexity, leading to more denials. There is also a growing focus from hospital CFOs on improving net patient revenue and reducing days in accounts receivable, making efficient denial management a direct financial priority.
Key adjacent markets include the broader revenue cycle management (RCM) software ecosystem, valued at an estimated $115.8 billion globally in 2023 (analogous market, source), and the clinical documentation improvement (CDI) segment, which aims to prevent denials at the point of coding. Regulatory forces are a constant factor; annual updates to ICD-10 and CPT codes, along with changing Medicare and Medicaid policies, require continuous software updates. The 21st Century Cures Act and related interoperability rules also push for more electronic data exchange, which could facilitate the integration Aegis describes.
The following table summarizes the key market sizing claims identified in public sources:
| Claim | Value | Source |
|---|---|---|
| Annual denied inpatient claims | ~$260B | [PMC], [Medical Economics] |
| Healthcare billing bottleneck | $300B | [Forbes, Aug 2025] |
| U.S. Healthcare IT market (2024) | $394.6B | Grand View Research, Jan 2025 (analogous) |
| Global RCM software market (2023) | $115.8B | Precedence Research, 2023 (analogous) |
The sizing claims for the core problem are consistent across multiple healthcare industry publications, which lends credibility to the magnitude of the operational inefficiency Aegis aims to address. However, translating a multi-hundred-billion-dollar claims problem into a viable software SAM requires clear segmentation, as the adjacent market data suggests the immediate software opportunity is an order of magnitude smaller.
Data Accuracy: YELLOW -- The $260B denial figure is cited by multiple healthcare trade publications but lacks a primary source citation. The adjacent market sizes are from analogous, dated third-party reports.
Competitive Landscape
MIXED Aegis enters a crowded, well-funded market for healthcare revenue cycle management with a sharp focus on a single, high-value workflow: automating insurance denial appeals.
Given the lack of named competitors in the structured sources, a direct comparison table is not possible. The competitive map must be constructed from the broader category. The landscape can be segmented into three tiers.
- Legacy RCM incumbents. This tier includes large public companies like R1 RCM and Cerner (now part of Oracle), which offer comprehensive revenue cycle suites that include denial management modules. Their advantage is an entrenched, enterprise-wide footprint within hospital systems. Their disadvantage is often the complexity and lack of automation in their legacy denial workflows, which Aegis aims to directly target [Forbes, Aug 2025].
- Modern software challengers. A newer generation of point solutions, such as CodaMetrix (for AI-powered coding) and Olive (for prior authorization), has emerged to automate specific, painful RCM tasks. These companies have raised significant venture capital and compete on modern APIs and AI claims. They represent the most direct competitive set for Aegis, though none cited in sources focus exclusively on the appeal letter generation and submission process.
- Adjacent substitutes and in-house solutions. The most common alternative is the manual status quo: dedicated hospital staff using spreadsheets and template documents. Adjacent substitutes also include general-purpose robotic process automation (RPA) tools like UiPath, which could be configured for denial workflows, and large consulting firms that offer revenue recovery as a service.
Aegis's stated edge is its end-to-end automation of a single, complex workflow, from detection to submission [Y Combinator, Spring 2025]. This specialization could allow for deeper product integration and more tailored AI models than broader suites provide. The durability of this edge is questionable, however, as it is primarily a product design choice. Incumbents could replicate a focused denial appeal agent, and well-funded challengers could pivot or expand into the niche. A more defensible, long-term edge would be built on proprietary data,specifically, a corpus of successful appeal letters and payer response patterns that continuously improves the AI's success rate. There is no public evidence yet that Aegis has accumulated such a dataset.
The company's most significant exposure is its lack of healthcare-specific distribution and regulatory experience. Selling into hospital billing departments requires navigating long sales cycles, complex procurement, and strict HIPAA compliance. Incumbents own these relationships and have established compliance frameworks. Aegis's founding team, while technically strong, has no publicly disclosed experience in healthcare sales, implementation, or navigating the payer-provider landscape. This inexperience presents a material go-to-market risk against established players.
Looking 18 months out, the most plausible competitive scenario is one of fragmentation and feature competition. A winner will emerge if one company can demonstrably prove its AI agents achieve a materially higher appeal win rate at a lower cost, securing lighthouse customers who publicly validate the ROI. A loser in this segment will be a company that remains a thin feature,a well-designed UI on top of a generic LLM,that fails to integrate deeply enough into hospital IT systems to become indispensable. For Aegis, the path to winning requires moving quickly from a promising Y Combinator demo to a deployed product with validated customer metrics that prove its specialized wedge is more effective than the alternatives.
Data Accuracy: YELLOW -- Competitive analysis is inferred from the broader market category; no direct competitors are named in available sources.
Opportunity
PUBLIC If Aegis can capture even a single percentage point of the $260 billion annual denial problem it targets, the revenue potential exceeds $2.5 billion.
The headline opportunity is to become the default operating system for healthcare revenue recovery. This is not merely an automation tool for a single workflow. The company's stated goal is to manage the "end-to-end" appeals process, from detection through analytics [Y Combinator, Spring 2025]. Success in this role would position Aegis as a critical, embedded layer in the financial operations of hospitals and large provider groups. The evidence that makes this outcome reachable, rather than purely aspirational, is the scale of the pain point. Multiple sources corroborate the annual value of denied inpatient claims at approximately $260 billion [PMC], [Medical Economics]. A platform that demonstrably recovers a material portion of that lost revenue would command significant enterprise value, as seen in comparable healthcare revenue cycle management (RCM) software vendors.
Growth could follow several distinct paths, each with a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Enterprise Land-and-Expand | Aegis wins a pilot with a major hospital system, then expands from a single department to system-wide deployment, and finally cross-sells into adjacent RCM workflows like prior authorization. | A publicly announced partnership or pilot with a named Top 100 U.S. health system. | The product's claimed integration with EHRs and payer portals is a prerequisite for enterprise sales [Y Combinator, Spring 2025]. The Forbes Technology Council platform provides a channel for founder visibility to potential enterprise buyers [Forbes Technology Council, 2025]. |
| API-First for Billing Firms | The company pivots its GTM to serve large, third-party medical billing companies as its primary customer, becoming an embedded AI layer within their existing tech stacks. | A shift in marketing language and a published API or partnership with a billing service. | The target buyer list includes "medical billing firms" [YouTube]. This segment aggregates denial volume across many providers, offering a faster path to scaling transaction volume without the long sales cycles of individual hospitals. |
Compounding for Aegis would manifest as a data and workflow moat. Each successfully appealed claim generates data on payer behavior, successful argumentation strategies, and provider-specific error patterns. This proprietary dataset could be used to train more effective appeal-generation models, creating a feedback loop where the system's success rate improves with scale. Furthermore, integration into a provider's or billing firm's daily operations creates significant switching costs. The platform's promised analytics to "reduce future denial rates" suggest an ambition to move beyond recovery to prevention, locking in customers by improving their core financial health [Y Combinator, Spring 2025].
The size of the win can be framed by looking at public comparables in adjacent healthcare IT sectors. For example, R1 RCM, a publicly traded revenue cycle management company, held a market capitalization of approximately $5.8 billion as of early 2025. A platform that automates a high-value, labor-intensive segment like denial appeals could command a premium multiple within that broader market. If the "Enterprise Land-and-Expand" scenario plays out and Aegis captures a low-single-digit share of its targeted denial value, it could support a valuation in the hundreds of millions to low billions of dollars (scenario, not a forecast). This upside is what makes the early-stage risk potentially worth underwriting for investors.
Data Accuracy: YELLOW -- Market size figures are cited by multiple industry publications but not by audited financial reports. Growth scenarios are extrapolated from stated product capabilities and target customers.
Sources
PUBLIC
[Y Combinator, Spring 2025] Aegis: AI Agents to win denied health insurance claims | https://www.ycombinator.com/companies/aegis
[Y Combinator, Spring 2025] Aegis AI Revenue Recovery Engine for Healthcare Providers | https://www.ycombinator.com/launches/NZg-aegis-ai-revenue-recovery-engine-for-healthcare-providers
[Crunchbase] Aegis - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/aegis-yc-x25
[GetLatka] Unknown | https://www.youtube.com/watch?v=ZS983q86caM
[PMC] Unknown | Not Provided
[Medical Economics] Unknown | Not Provided
[Forbes, Aug 2025] Healthcare’s $300 Billion Bottleneck: Why Billing Is The Next Big AI Battleground | https://www.forbes.com/councils/forbestechcouncil/2025/08/25/healthcares-300-billion-bottleneck-why-billing-is-the-next-big-ai-battleground/
[Forbes Technology Council, 2025] Dhanya Shah | Co-Founder & COO - Aegis Health Technology Corporation | Forbes Technology Council | https://councils.forbes.com/profile/Dhanya-Shah-Co-Founder-COO-Aegis-Health-Technology-Corporation/6042a442-0b42-4fc2-995c-e94fb703f59e
[Forbes Technology Council, 2025] Krishang Todi - Forbes Technology Council | https://www.forbes.com/councils/forbestechcouncil/people/krishangtodi/
[Grand View Research, Jan 2025] Unknown | Not Provided
[Precedence Research, 2023] Unknown | Not Provided
Articles about Aegis
- Aegis's AI Engine Aims to Recover the $260 Billion Left on the Table in Medical Billing — The Y Combinator-backed startup is automating insurance denial appeals, a manual process that costs hospitals billions and delays patient care.